BBSRC Portfolio Analyser
Award details
Feasibility study to determine whether new generation catalytic antibodies can overcome existing limitations for future use in clinical settings.
Reference
BB/N012356/1
Principal Investigator / Supervisor
Professor Nigel Scrutton
Co-Investigators /
Co-Supervisors
Institution
The University of Manchester
Department
Chemistry
Funding type
Research
Value (£)
119,422
Status
Completed
Type
Research Grant
Start date
01/07/2016
End date
30/06/2017
Duration
12 months
Abstract
Research into the therapeutic use of catalytic antibodies stretches back over 30 years but to date there is not a single example of success in the clinic. This is in stark contrast to the ever-expanding use of antibodies to treat a range of diseases when they are used as binders and modulators of protein function. This feasibility study aims to answer whether this imbalance can be redressed through the utilisation of novel techniques now available in antibody research (specifically improved antibody phage libraries and bispecific antibody technologies) combined with an examination of the therapeutic and commercial potential of catalytic antibodies should the primary issues of poor catalytic efficiency and selectivity as compared to the natural enzymes be addressed. As a test case we have chosen to try and make catalytic antibodies that share the therapeutically useful properties of streptococcal IgG endopeptidase but lack the enzyme's immunogenicity, which seriously limits its clinical potential.
Summary
Research into the therapeutic use of catalytic antibodies stretches back over 30 years but to date there is not a single example of success in the clinic. This is in stark contrast to the ever-expanding use of antibodies to treat a range of diseases when they are used as binders and modulators of protein function. This feasibility study aims to answer whether this imbalance can be redressed through the utilisation of novel techniques now available in antibody research (specifically improved antibody phage libraries and bispecific antibody technologies) combined with an examination of the therapeutic and commercial potential of catalytic antibodies should the primary issues of poor catalytic efficiency and selectivity as compared to the natural enzymes be addressed. As a test case we have chosen to try and make catalytic antibodies that share the therapeutically useful properties of streptococcal IgG endopeptidase but lack the enzyme's immunogenicity, which seriously limits its clinical potential.
Impact Summary
As described in proposal submitted to TSB
Committee
Not funded via Committee
Research Topics
Industrial Biotechnology, Pharmaceuticals
Research Priority
X – Research Priority information not available
Research Initiative
Industrial Biotechnology Catalyst (IBCAT) [2014-2015]
Funding Scheme
X – not Funded via a specific Funding Scheme
I accept the
terms and conditions of use
(opens in new window)
export PDF file
back to list
new search